U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07357220) titled 'A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases' on Dec. 24, 2025.
Brief Summary: An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.
Study Start Date: March 02
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer With Hepatic Metastases
Intervention:
BIOLOGICAL: VG2025
Recommended Phase II Dose, Intratumoral Injection, Q4W
DRUG: AK112
20mg/kg, ivgtt, Q2W
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Akeso
Published by HT Digital Content Services with permission from Health Daily Digest....